Tenaya Therapeutics, Inc. (TNYA): who owns it and who trades it
As of Nov 16, 2026, TNYA insiders reported 33 open-market sales worth $6M and no purchases in the last 12 months, with 0% of the sale value made under pre-set 10b5-1 plans. The largest seller was Column Group Iii-A, Lp (10% owner), with $3.5M. 3 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Tenaya Therapeutics
From the latest filingsOverall: more selling than buying. Insiders and famous investors mostly sold. Funds was close to even.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns TNYA
101 funds and institutions reported TNYA shares worth $39.7M at the end of Q2 2026, about 25% of the company. The largest holder is Vanguard Capital Management LLC with 3.3%.
Funds and institutions (13F) 25%Everyone else 75%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| Vanguard Capital Management LLC | 7.10M | 3.27% | $5.2M | -16% |
| Millennium Management LLC | 6.43M | 2.96% | $4.8M | +18% |
| Citadel Advisors LLC | 4.57M | 2.10% | $3.4M | +9% |
| Renaissance Technologies LLC | 4.28M | 1.97% | $3.2M | +15% |
| BlackRock, Inc. | 4.01M | 1.85% | $3M | +8% |
| Empery Asset Management, LP | 3.86M | 1.78% | $2.9M | -10% |
| Marshall Wace, LLP | 3.50M | 1.61% | $2.6M | +29% |
| Gsa Capital Partners LLP | 2.67M | 1.23% | $2M | +149% |
| Burkehill Global Management, LP | 2.00M | 0.92% | $1.5M | No change |
| Geode Capital Management, LLC | 1.83M | 0.85% | $1.4M | +18% |
| ADAR1 Capital Management, LLC | 1.56M | 0.72% | $1.1M | +3% |
| Raiffeisen Bank International AG | 1.20M | 0.55% | $882K | +20% |
| Euclidean Capital LLC | 1.02M | 0.47% | $751K | No change |
| Vanguard Fiduciary Trust Co | 987,505 | 0.46% | $730K | -3% |
| Mirador Capital Partners LP | 905,097 | 0.42% | $669K | +2% |
| State Street Corp | 708,721 | 0.33% | $524K | No change |
| Squarepoint Ops LLC | 659,247 | 0.30% | $487K | +89% |
| StepStone Group LP | 462,163 | 0.21% | $342K | No change |
| UBS Group AG | 456,555 | 0.21% | $337K | -31% |
| Jane Street Group, LLC | 450,435 | 0.21% | $333K | -62% |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, TNYA insiders reported $0 of open-market purchases and $6M of sales. 0% of the sale value was under a 10b5-1 plan, a schedule set up in advance.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Aug 17, 2026 | Faraz Ali | CEO | Sale | 5,020 | $0.71 | $3.6K | Form 4 |
| Aug 17, 2026 | Faraz Ali | CEO | Sale | 7,406 | $0.71 | $5.3K | Form 4 |
| Aug 17, 2026 | Faraz Ali | CEO | Sale | 5,837 | $0.71 | $4.1K | Form 4 |
| Aug 17, 2026 | Faraz Ali | CEO | Sale | 3,969 | $0.71 | $2.8K | Form 4 |
| Aug 17, 2026 | Whittemore Tingley | Chief Medical Officer | Sale | 1,637 | $0.71 | $1.2K | Form 4 |
| Aug 17, 2026 | Whittemore Tingley | Chief Medical Officer | Sale | 1,871 | $0.71 | $1.3K | Form 4 |
| Aug 17, 2026 | Whittemore Tingley | Chief Medical Officer | Sale | 2,279 | $0.71 | $1.6K | Form 4 |
| May 18, 2026 | Faraz Ali | CEO | Sale | 3,390 | $0.79 | $2.7K | Form 4 |
| May 18, 2026 | Whittemore Tingley | Chief Medical Officer | Sale | 3,121 | $0.79 | $2.5K | Form 4 |
| May 18, 2026 | Tomohiro Higa | Vice president | Sale | 1,485 | $0.79 | $1.2K | Form 4 |
| Feb 25, 2026 | TCG Opportunity III GP, LLC +7 | 10% owner | Sale | 1.65M | $0.56 | $924K | Form 4 |
| Feb 25, 2026 | TCG Opportunity III GP, LLC +7 | 10% owner | Sale | 1.86M | $0.56 | $1M | Form 4 |
| Feb 24, 2026 | TCG Opportunity III GP, LLC +7 | 10% owner | Sale | 349,212 | $0.62 | $217K | Form 4 |
| Feb 24, 2026 | TCG Opportunity III GP, LLC +7 | 10% owner | Sale | 309,228 | $0.62 | $192K | Form 4 |
| Feb 23, 2026 | Column Group Iii-A, Lp +7 | 10% owner | Sale | 162,291 | $0.60 | $97.4K | Form 4 |
| Feb 23, 2026 | Column Group Iii-A, Lp +7 | 10% owner | Sale | 143,709 | $0.60 | $86.2K | Form 4 |
| Feb 20, 2026 | Column Group Iii-A, Lp +7 | 10% owner | Sale | 277,769 | $0.61 | $169K | Form 4 |
| Feb 20, 2026 | Column Group Iii-A, Lp +7 | 10% owner | Sale | 245,965 | $0.61 | $150K | Form 4 |
| Feb 17, 2026 | Tomohiro Higa | Vice president | Sale | 836 | $0.64 | $535 | Form 4 |
| Feb 17, 2026 | Tomohiro Higa | Vice president | Sale | 2,022 | $0.64 | $1.3K | Form 4 |
| Feb 17, 2026 | Tomohiro Higa | Vice president | Sale | 611 | $0.64 | $391 | Form 4 |
| Feb 17, 2026 | Faraz Ali | CEO | Sale | 5,032 | $0.64 | $3.2K | Form 4 |
| Feb 17, 2026 | Faraz Ali | CEO | Sale | 5,851 | $0.64 | $3.7K | Form 4 |
| Feb 17, 2026 | Faraz Ali | CEO | Sale | 3,979 | $0.64 | $2.5K | Form 4 |
| Feb 17, 2026 | Whittemore Tingley | Chief Medical Officer | Sale | 1,642 | $0.64 | $1.1K | Form 4 |
| Feb 17, 2026 | Whittemore Tingley | Chief Medical Officer | Sale | 1,876 | $0.64 | $1.2K | Form 4 |
| Feb 11, 2026 | Column Group Iii-A, Lp +7 | 10% owner | Sale | 2.15M | $0.68 | $1.5M | Form 4 |
| Feb 11, 2026 | Column Group Iii-A, Lp +7 | 10% owner | Sale | 1.91M | $0.68 | $1.3M | Form 4 |
| Feb 10, 2026 | Column Group Iii-A, Lp +7 | 10% owner | Sale | 161,422 | $0.82 | $132K | Form 4 |
| Feb 10, 2026 | Column Group Iii-A, Lp +7 | 10% owner | Sale | 182,295 | $0.82 | $149K | Form 4 |
| Nov 17, 2025 | Tomohiro Higa | Vice president | Sale | 1,367 | $1.33 | $1.8K | Form 4 |
| Nov 17, 2025 | Whittemore Tingley | Chief Medical Officer | Sale | 2,877 | $1.33 | $3.8K | Form 4 |
| Nov 17, 2025 | Faraz Ali | CEO | Sale | 3,126 | $1.33 | $4.2K | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Column Group Iii-A, Lp | 10% owner | – | $3.5M | Feb 23, 2026 |
| TCG Opportunity III GP, LLC | 10% owner | – | $2.4M | Feb 25, 2026 |
| Faraz Ali | Chief Executive Officer, Director | – | $32.1K | Aug 17, 2026 |
| Whittemore Tingley | Chief Medical Officer | – | $12.7K | Aug 17, 2026 |
| Tomohiro Higa | SVP, Finance | – | $5.2K | May 18, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
TNYA short interest
High short interest. 10.3% of TNYA shares are sold short: about 1 share in 10. Over the last 12 reports the number of shares short went down 19%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 23.41M TNYA shares were sold short, 10.3% of the shares outstanding, up 4.0% from the report before. At the average daily volume of 2.69M shares, buying them all back would take about 8.7 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 23.41M | 10.27% | +4% | 2.69M | 8.7 |
| Oct 15, 2026 | 22.52M | 10.04% | -2% | 4.86M | 4.6 |
| Sep 30, 2026 | 22.92M | 10.22% | +6% | 3.04M | 7.5 |
| Sep 15, 2026 | 21.64M | 9.65% | +4% | 1.70M | 12.8 |
| Aug 31, 2026 | 20.77M | 9.26% | -2% | 1.96M | 10.6 |
| Aug 14, 2026 | 21.10M | 9.41% | -4% | 2.11M | 10.0 |
| Jul 31, 2026 | 21.99M | 9.81% | -12% | 1.60M | 13.7 |
| Jul 15, 2026 | 24.92M | 11.48% | -5% | 3.36M | 7.4 |
| Jun 30, 2026 | 26.23M | 12.09% | -8% | 2.02M | 13.0 |
| Jun 15, 2026 | 28.66M | 13.21% | -2% | 3.41M | 8.4 |
| May 29, 2026 | 29.30M | 13.50% | +2% | 3.09M | 9.5 |
| May 15, 2026 | 28.75M | 13.25% | +3% | 6.52M | 4.4 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Tenaya Therapeutics company events
Tenaya Therapeutics filed 12 reports on Form 8-K in the last 12 months, 4 of them about an important change (leadership, listing). The latest was on Nov 4, 2026.
- Nov 4, 2026ResultsReleased financial results. Filing
- Aug 5, 2026ResultsReleased financial results. Filing
- Jul 2, 2026AgreementEnded an important agreement. Filing
- Jun 29, 2026LeadershipTenaya Therapeutics, Inc. announced that Eric Hyllengren, M.B.A., will join the Company as Chief Financial Officer on July 13, 2026, and in such capacity, will serve as the Company’s Principal Financial Officer and Principal Accounting Officer beginning on the Commencement Date. Filing
- May 29, 2026LeadershipTenaya Therapeutics, Inc. amended and restated its 2021 Equity Incentive Plan, effective as of May 27, 2026 upon approval by the stockholders of the Company at the Annual Meeting (as defined below). Filing
- May 6, 2026ResultsReleased financial results. Filing
- Mar 11, 2026ResultsReleased financial results. Filing
- Mar 5, 2026AgreementTenaya Therapeutics, Inc. entered into a collaboration agreement with Alnylam Pharmaceuticals, Inc., pursuant to which the parties agreed to a research collaboration to discover and validate novel gene targets for the potential treatment of cardiovascular disease. Filing
- Jan 30, 2026ListingTenaya Therapeutics, Inc. received a letter from the Listing Qualifications Staff of The Nasdaq Stock Market LLC indicating that, based upon the closing bid price of shares of the Company’s common stock for the 30 consecutive business day period between December 12, 2025, through January 27, 2026… Filing
- Jan 2, 2026LeadershipIn connection with his retirement, David Goeddel submitted his resignation from the board of directors of Tenaya Therapeutics, Inc. and as a member of all committees of the Board, effective January 26, 2026. Filing
- Dec 12, 2025AgreementTenaya Therapeutics, Inc. entered into an underwriting agreement with Leerink Partners LLC and Piper Sandler & Co., as representatives of the underwriters listed therein, relating to the issuance and sale in a firm commitment underwritten public offering of 50,000,000 units, at a public offering… Filing
- Dec 11, 2025AnnouncementFollowing proactive correspondence with the FDA relating to future development plans for TN-201, on November 7, 2025, the Company announced that the FDA placed MyPEAK-1 on clinical hold requesting an amendment to the protocol primarily to standardize activities related to patient monitoring and… Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Tenaya Therapeutics financials
Famous investors that hold TNYA
3 of the 50 well-known investors we track reported holding TNYA in their latest 13F filing. The largest position is Israel Englander's, worth $6.2M.
Position size
All holders
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Israel Englander · Millennium Management | Q3 2026 | 10.24M | $6.2M | 0.0% | +59% |
| Ken Griffin · Citadel Advisors | Q3 2026 | 4.51M | $2.7M | 0.0% | -1% |
| Jim Simons · Renaissance Technologies | Q3 2026 | 2.96M | $1.8M | 0.0% | -31% |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 2 filings named TNYA in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Nov 16, 2026 | The Column Group Opportunity III, LP | 13D/A | 21.6% |
| Nov 16, 2026 | The Column Group Opportunity III, LP | 13D/A | 21.6% |
Questions about Tenaya Therapeutics, Inc. (TNYA) stock
Who owns the most TNYA stock?
The largest reported owner of Tenaya Therapeutics, Inc. (TNYA) is Vanguard Capital Management LLC, with 3.3% of the company. In total, 101 funds and institutions reported holding TNYA at the end of Q2 2026, together about 25% of the shares. See the largest owners.
Are TNYA insiders buying or selling?
In the last 12 months, TNYA insiders reported no open-market purchases and 33 sales worth $6M. The latest trade was on Aug 17, 2026. See every trade.
What is the short interest in TNYA?
As of Oct 30, 2026, 23.41M TNYA shares were sold short, 10.3% of the shares outstanding, up 4.0% from the report before. At the average daily volume of 2.69M shares, buying them all back would take about 8.7 trading days (days to cover). See the history.
Which famous investors hold TNYA?
3 of the 50 well-known investors we track reported TNYA in their latest 13F filing, including Israel Englander, Ken Griffin, Jim Simons. The largest position is worth $6.2M. See all holders.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.